News Story Friday, June 18, 2021

Treatment adherence in patients with type 2 diabetes

Less than 50% of patients with diabetes achieve the glycaemic goals recommended by the American Diabetes Association. The set of factors associated with adherence to treatment is very broad. Evidence suggests that psychosocial factors are related to medication adherence of patients with type 2 diabetes.

Study here:


This year marks the 100th anniversary of insulin discovery.


Ontario Pharmacists Association (OPA) is proud to announce a partnership with BD Canada and Ascensia Diabetes Care to celebrate the momentous anniversary and highlight the important involvement of pharmacy professionals in managing the disease.

Check out the series of online events and programs.


News Story Monday, November 30, 2020

An interesting article was written by Thomas E. Sullivan, M.D. about 3 Ways Technology Can Promote Medication Adherence

An interesting article was written by Thomas E. Sullivan, M.D. about 3 Ways Technology Can Promote Medication Adherence by People with Diabetes. Diabetes is somewhat unique among the diseases of the 21st century, even though it’s been known for thousands of years. Although both Type 1 and Type 2 diabetes are potentially fatal, most patients can live a very long life with proper care, treatment and lifestyle changes. See what he said.


News Story Friday, October 23, 2020

Prime Therapeutics researchers studied hypertension, cholesterol and diabetes medications. See the results here.

They found with a population of over 567,000, sample sizes for each drug category and their associated total cost of care savings – from moving someone with low adherence (<50%) to near perfect adherence (99%+) – was as follows:
- RAS: 132,358 in the sample, achieving $2,901 potential savings PPPY
- Statin: 145,038 in the sample, achieving $1,563 potential savings PPPY
- Diabetes: 40,407 in the sample, achieving $3,365 potential savings PPPY
Additionally, the study found lower odds of hospitalizations and emergency room visits were associated with improved drug category adherence.


DayaMed Arthur technology is ideal for Payers and Insurance companies that are looking for a solution to reduce their costs.

Our Arthur platform is excellent for using medication adherence to manage chronic illness. Learn how Arthur can give Payers and Insurance companies a competitive advantage.


News Story Monday, April 13, 2020

DayaMed Arthur technology is perfect for insurance companies.

75% of the healthy insured population, support 5% of the insured members who are most chronically ill. These chronic illnesses, primarily diabetes, high cholesterol, and high blood pressure, are preventable and treatable. However, when patient compliance goes down, disease incidents increase, inflating insurance premiums even for those without illness. Arthur's ability to improve a patient's compliance with their therapeutic regimen as well as inform insurance companies about the patient's compliance status not only improves that patient's health but lowers healthcare costs for everyone. Insurance companies now have the ability to base incentives on a patient's compliance with their treatment regimen while implementing a value-based insurance design.




Copyright © 2021 Daya Medicals Inc. | PRIVACY | SITEMAP